Christine Janson
Director, Translational Pharmacology Exelixis, Inc.
Seminars
Monday 12th October 2026
Evaluating Design & Preclinical Characterization of XB404, a Masked ADC Targeting ROR1 & ROR2
9:30 am
- Breaking down design of XB404 leveraging Adagene and SMARTag platforms to develop a masked ADC targeting ROR1/2
- Emphasizing rationale of XB404 masked mechanism to minimize on target, off tumor safety in ROR1/2 expressing tumors
- Laying out preclinical characterization across in vitro cytotoxicity and bystander activity and in vivo efficacy in CDX and PDX models
